美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Obsidian Therapeutics Inc

12.24

-0.9600-7.27%

盤後：12.20-0.0400-0.33%19:32 EDT

成交量：51.72萬

成交額：642.22萬

市值：7.56億

市盈率：-0.38

高：13.39

開：13.14

低：12.07

收：13.20

52周最高：49.97

52周最低：12.07

股本：6,172.72萬

流通股本：5,295.45萬

量比：1.88

換手率：0.98%

股息：- -

股息率：- -

每股收益(TTM):-31.8407

每股收益(LYR):-2,056.1834

淨資產收益率：--

總資產收益率：--

市淨率：-2.52

市盈率(LYR):-0.01

資料載入中...

總覽公司新聞資訊公告

Leerink Partners首予Obsidian Therapeutics「跑贏大盤」評級，目標價定為每股32美元

Obsidian Therapeutics提交招股説明書，涉及最多29,164,045股普通股轉售

Obsidian Therapeutics宣佈：晚期黑色素瘤新藥Amsoki-Cel (Obx-115) 關鍵註冊隊列首例患者成功入組

美國研究綜述-Ametek、Ball Corp、麥當勞

美國研究綜述-Ametek、Ball Corp、麥當勞

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/OBX/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OBX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OBX\",,,,,undefined,":{"symbol":"OBX","market":"US","secType":"STK","nameCN":"Obsidian Therapeutics Inc","latestPrice":12.24,"timestamp":1791489600000,"preClose":13.2,"halted":0,"volume":517206,"hourTrading":{"tag":"盘后","latestPrice":12.2,"preClose":12.24,"latestTime":"19:32 EDT","volume":5426,"amount":66423.1,"timestamp":1791502371088,"change":-0.04,"changeRate":-0.003268,"amplitude":0.003268},"delay":0,"changeRate":-0.07272727272727265,"floatShares":52954500,"shares":61727211,"eps":-31.840738,"marketStatus":"未開盤","change":-0.96,"latestTime":"10-08 16:00:00 EDT","open":13.14,"high":13.39,"low":12.07,"amount":6422203.536057,"amplitude":0.1,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-31.840738,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1791532800000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":13.2,"preHourTrading":{"tag":"盘前","latestPrice":13.2,"preClose":13.2,"latestTime":"08:11 EDT","volume":20,"amount":264,"timestamp":1791461462794,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":12.2,"preClose":12.24,"latestTime":"19:32 EDT","volume":5426,"amount":66423.1,"timestamp":1791502371088,"change":-0.04,"changeRate":-0.003268,"amplitude":0.003268},"volumeRatio":1.879635},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OBX\",,,,,undefined,":{"symbol":"OBX","floatShares":52954500,"roa":"--","roe":"--","lyrEps":-2056.183449,"volumeRatio":1.879635,"shares":61727211,"dividePrice":0,"high":13.39,"amplitude":0.1,"preClose":13.2,"low":12.07,"week52Low":12.07,"pbRate":"-2.52","week52High":49.9699,"institutionHeld":0,"latestPrice":12.24,"eps":-31.840738,"divideRate":0,"volume":517206,"delay":0,"ttmEps":-31.840738,"open":13.14,"prevYearClose":49.9699,"prevWeekClose":13.59,"prevMonthClose":13.73,"prevQuarterClose":13.73,"fiveDayClose":13.32,"twentyDayClose":17.16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OBX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-04","symbol":"OBX","defaultRemindTime":1785850200000,"type":"split","dateTimestamp":1785816000000,"forFactor":10000,"toFactor":7019,"ratio":1.4247043738424277}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OBX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OBX\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OBX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OBX","date":"2026-10-07","current":-0.384413,"percent":0.756098,"low":-15.919767,"twenty":-11.604295,"median":-9.371112,"eighty":-8.613049,"high":-7.414063,"avg":-10.182143,"sd":1.914033,"marketCap":816637420},"quantilePoints":[{"date":"2026-08-14","current":-8.605771,"twenty":-15.155618,"median":-12.735814,"eighty":-11.727865,"marketCap":819734144},{"date":"2026-08-21","current":-9.183431,"twenty":-13.181567,"median":-9.14022,"eighty":-8.501155,"marketCap":874758582},{"date":"2026-08-28","current":-7.750652,"twenty":-12.553874,"median":-9.051525,"eighty":-8.311938,"marketCap":738280646},{"date":"2026-09-04","current":-11.204373,"twenty":-11.465176,"median":-9.062896,"eighty":-8.061315,"marketCap":1055698450},{"date":"2026-09-11","current":-11.250266,"twenty":-12.259905,"median":-9.14022,"eighty":-8.254627,"marketCap":1060022552},{"date":"2026-09-18","current":-11.473173,"twenty":-12.018641,"median":-11.145368,"eighty":-8.451122,"marketCap":1081025330},{"date":"2026-09-25","current":-8.791729,"twenty":-11.748529,"median":-11.145368,"eighty":-8.565744,"marketCap":828374267},{"date":"2026-10-02","current":-8.732724,"twenty":-11.650188,"median":-10.004607,"eighty":-8.565744,"marketCap":822814708},{"date":"2026-10-07","current":-8.667163,"twenty":-11.604295,"median":-9.371112,"eighty":-8.613049,"marketCap":816637420}],"updateTime":1791510233568},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OBX\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1118547263","title":"Leerink Partners首予Obsidian Therapeutics「跑贏大盤」評級，目標價定為每股32美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1118547263","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118547263?lang=zh_tw&edition=fundamental","pubTime":"2026-09-22 18:09","pubTimestamp":1790071749,"startTime":"0","endTime":"0","summary":"Leerink Partners近日正式启动对Obsidian Therapeutics Inc（简称Obsidian Therapeutics）的覆盖研究，并给出“跑赢大盘”的初始评级。与此同时，该机构将这家公司的目标股价设定为每股32美元。此举标志着投行对这家生物科技领域新兴力量的关注度正显著提升。值得注意的是，Leerink Partners的这份评级报告，为投资者提供了关于Obsidian Therapeutics未来发展潜力的全新视角。在当下竞争激烈的市场环境中，这一目标价显然反映出机构对其前景抱有一定程度的乐观预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180960798","title":"Obsidian Therapeutics提交招股説明書，涉及最多29,164,045股普通股轉售","url":"https://stock-news.laohu8.com/highlight/detail?id=1180960798","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180960798?lang=zh_tw&edition=fundamental","pubTime":"2026-08-29 05:13","pubTimestamp":1787951593,"startTime":"0","endTime":"0","summary":"Obsidian Therapeutics Inc已向美国证券交易委员会提交了一份招股说明书，内容涉及出售股东转售最多29,164,045股普通股。此次提交的招股说明书并未涉及公司自身的资金募集行为，而是旨在为股东提供一个合规的转售平台。值得关注的是，Obsidian Therapeutics专注于细胞疗法的开发，其核心研发管线正处於临床前及早期临床阶段。此类公司的股价对融资及股东活动尤为敏感，本次提交的招股书亦将成为投资者近期评估该公司股票供需关系的关键参考。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160444967","title":"Obsidian Therapeutics宣佈：晚期黑色素瘤新藥Amsoki-Cel (Obx-115) 關鍵註冊隊列首例患者成功入組","url":"https://stock-news.laohu8.com/highlight/detail?id=1160444967","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160444967?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 19:06","pubTimestamp":1785927982,"startTime":"0","endTime":"0","summary":"Obsidian Therapeutics公司今日重磅宣布，其针对晚期黑色素瘤的细胞疗法——Amsoki-Cel（原名Obx-115），在1/2期Agni-01研究的注册导向队列中，已成功完成首例患者入组。这一里程碑事件，标志着该创新疗法正式迈入关键性临床开发阶段，为全球黑色素瘤患者带来了全新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657519496","title":"美國研究綜述-Ametek、Ball Corp、麥當勞","url":"https://stock-news.laohu8.com/highlight/detail?id=2657519496","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657519496?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 15:57","pubTimestamp":1785916639,"startTime":"0","endTime":"0","summary":"美国研究综述-Ametek、Ball Corp、麦当劳路透8月5日-周三，华尔街证券分析师下调了多家在美国上市公司的评级和目标股价，其中包括阿美特克、鲍尔公司和麦当劳。要点* 阿美特克AME.N：加拿大皇家银行将目标价从260美元上调至291美元* 博尔公司BALL.N：摩根大通将评级从“增持”下调至“中性”* 麦当劳MCD.N：摩根大通将目标价从305美元下调至280美元以下是路透周三报道的针对美国公司的研究报告摘要。股票按字母顺序排列。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL4S4420OI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PINS","TVTX","JXN","PRCT","TPG","MCD","ANET","CMI","TOST","OPLN","BBY","HSIC","PLTR","W","BALL","PPLI","ALAB","CAT","MKL","WAT","BKNG","ZBRA","EMR","FBIN","GILD","AME","LMAT","AMD","HLNE","KTOS","NPO","YETI","BDX","ARWR","CINF","QLYS","SYY","PCTY","IT","BR","BRKR","HNGE","OBX","LSCC","AMGN","XMTR","MRK","SPCX","BL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657499519","title":"美國研究綜述-Ametek、Ball Corp、麥當勞","url":"https://stock-news.laohu8.com/highlight/detail?id=2657499519","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657499519?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 15:57","pubTimestamp":1785916639,"startTime":"0","endTime":"0","summary":"美国研究综述-Ametek、Ball Corp、麦当劳路透8月5日-周三，华尔街证券分析师下调了多家在美国上市公司的评级和目标股价，其中包括阿美特克、鲍尔公司和麦当劳。要点* 阿美特克AME.N：加拿大皇家银行将目标价从260美元上调至291美元* 博尔公司BALL.N：摩根大通将评级从“增持”下调至“中性”* 麦当劳MCD.N：摩根大通将目标价从305美元下调至280美元以下是路透周三报导的针对美国公司的研究报告摘要。股票按字母顺序排列。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL4T4420OI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PINS","TVTX","JXN","PRCT","TPG","MCD","ANET","CMI","TOST","OPLN","BBY","HSIC","PLTR","W","BALL","PPLI","ALAB","CAT","MKL","WAT","BKNG","ZBRA","EMR","FBIN","GILD","AME","LMAT","AMD","HLNE","KTOS","NPO","YETI","BDX","ARWR","CINF","QLYS","SYY","PCTY","IT","BR","BRKR","HNGE","OBX","LSCC","AMGN","MRK","SPCX","BL"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}